From Anthracyclines to Immunotherapy: Cardiotoxicity in the Era of AI and Precision Oncology
Thursday, Sept. 25 | 12 p.m. – 1 p.m. ET | CTW 312
 
 
SPEAKER:
Tochukwu Okwuosa, DO, FACC, FAHA Director, Cardio-Oncology Program
Rush University Medical Center in Chicago
Dr. Okwuosa is the Immediate Past Chair of the AHA Cardio-Oncology Committee and an Associate Editor for the Journal of the American Heart Association. Her primary research interests lie in the areas of Cardio- Oncology and Cardiovascular Disease Prevention. She has played a crucial role in launching several successful local, regional, and national initiatives aimed at advancing Cardio-Oncology and enhancing medical education, while also promoting collaboration within the medical community.
 
To join from PC, Mac, iOS or Android: https://uky.zoom.us/j/7323732840
You may be prompted to enter a password: 729589
To join by audio only from a telephone, dial: 408-638-0968 or 646-558-8656
Meeting ID: 7323732840
 
  After this session participants will be able to:
  1. Review epidemiology and advances in cardio-oncology care.
  2. Discuss cases and common cardiovascular toxicities of common cancer therapies.
  3. Identify the Landscape of Precision Medicine, Machine/Deep Learning & AI in Cardio-Oncology.
Disclosure of Financial Interest Summary to Learners

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies. The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the  speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing  investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Session date: 
10/23/2025 - 12:00pm to 1:00pm EDT
Location: 
UK Gill Heart & Vascular Institute
900 S. Limestone Street
CT Wethington Bldg, Room 312
Lexington, KY
United States
See map: Google Maps
  • 1.00 ACPE

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

  • 1.00 AMA PRA Category 1 Credit™

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This Enduring activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC (UK Healthcare CECentral)

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour(s).

  • 1.00 Participation
    UK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.
Please login or register to take this course.